恶性疟原虫的重组Pfs25蛋白在实验动物中引发疟疾传播阻断免疫。
Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.
作者信息
Barr P J, Green K M, Gibson H L, Bathurst I C, Quakyi I A, Kaslow D C
机构信息
Chiron Corporation, Emeryville, California 94608.
出版信息
J Exp Med. 1991 Nov 1;174(5):1203-8. doi: 10.1084/jem.174.5.1203.
Abstract
Pfs25 is a sexual stage antigen of Plasmodium falciparum that is expressed on the surface of zygote and ookinete forms of the parasite. Monoclonal antibodies directed against native Pfs25 can block completely the development of P. falciparum oocysts in the midgut of the mosquito vector. Thus, this 25-kD protein is a potential vaccine candidate for eliciting transmission-blocking immunity in inhabitants of malaria endemic regions. We have synthesized, by secretion from yeast, a polypeptide analogue of Pfs25 that reacts with conformation-dependent monoclonal antibodies, and elicits transmission-blocking antibodies when used to immunize mice and monkeys in conjunction with a muramyl tripeptide adjuvant. Our results suggest the further evaluation of recombinant DNA-derived Pfs25 in transmission-blocking vaccination studies in humans.
摘要
Pfs25是恶性疟原虫的一种性阶段抗原，在该寄生虫的合子和动合子形式的表面表达。针对天然Pfs25的单克隆抗体可完全阻断恶性疟原虫卵囊在蚊媒中肠的发育。因此，这种25-kD蛋白是一种潜在的疫苗候选物，可在疟疾流行地区的居民中引发传播阻断免疫。我们通过酵母分泌合成了一种Pfs25的多肽类似物，它能与构象依赖性单克隆抗体发生反应，并且在与胞壁酰三肽佐剂联合用于免疫小鼠和猴子时能引发传播阻断抗体。我们的结果表明，在人类传播阻断疫苗接种研究中应进一步评估重组DNA衍生的Pfs25。
相似文献
1
Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.恶性疟原虫的重组Pfs25蛋白在实验动物中引发疟疾传播阻断免疫。
J Exp Med. 1991 Nov 1;174(5):1203-8. doi: 10.1084/jem.174.5.1203.
2
Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.用一种疟疾传播阻断候选疫苗Pfs25进行鼻腔免疫，可在小鼠中诱导出针对恶性疟原虫野外分离株的完全保护性免疫。
Infect Immun. 2005 Nov;73(11):7375-80. doi: 10.1128/IAI.73.11.7375-7380.2005.
3
A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.一种新型植物生产的Pfs25融合亚单位疫苗可诱导持久的传播阻断抗体反应。
Hum Vaccin Immunother. 2015;11(1):124-32. doi: 10.4161/hv.34366. Epub 2014 Nov 1.
4
Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus.
Science. 1991 May 31;252(5010):1310-3. doi: 10.1126/science.1925544.
5
6
Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice.酿酒酵母分泌的融合蛋白Pfs25和Pfs28在小鼠体内引发强效的恶性疟原虫传播阻断抗体。
Infect Immun. 1998 Jan;66(1):59-64. doi: 10.1128/IAI.66.1.59-64.1998.
7
Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.疟疾候选疫苗Pfs25/Pvs25诱导的传播阻断活性是抗体滴度的直接且可预测的函数。
Malar J. 2007 Aug 8;6:107. doi: 10.1186/1475-2875-6-107.
8
Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.用与人用兼容的强效佐剂配制的藻类产生的疟疾传播阻断疫苗候选物Pfs25可诱导高亲和力抗体，这些抗体可阻断恶性疟原虫对蚊子的感染。
Infect Immun. 2015 May;83(5):1799-808. doi: 10.1128/IAI.02980-14. Epub 2015 Feb 17.
9
A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies.恶性疟原虫抗原Pfs25的一个区域，该区域是高效传播阻断抗体的靶点。
Infect Immun. 2000 Oct;68(10):5530-8. doi: 10.1128/IAI.68.10.5530-5538.2000.
10
Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum.吸附于明矾的酿酒酵母重组Pfs25可引发能阻断恶性疟原虫传播的抗体。
Infect Immun. 1994 Dec;62(12):5576-80. doi: 10.1128/iai.62.12.5576-5580.1994.
引用本文的文献
1
Malaria Vaccines: Current Achievements and Path Forward.疟疾疫苗：当前成果与未来之路
Vaccines (Basel). 2025 May 19;13(5):542. doi: 10.3390/vaccines13050542.
2
mosGILT antibodies interfere with Plasmodium sporogony in Anopheles gambiae.mosGILT抗体干扰冈比亚按蚊体内疟原虫的孢子生殖。
Nat Commun. 2025 Jan 11;16(1):592. doi: 10.1038/s41467-025-55902-1.
3
Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in Plasmodium falciparum.多样性和选择分析将阻断传播的抗原确定为恶性疟原虫的最佳疫苗候选物。
EBioMedicine. 2024 Aug;106:105227. doi: 10.1016/j.ebiom.2024.105227. Epub 2024 Jul 16.
4
Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in .多样性和选择分析确定传播阻断抗原是……中最佳的疫苗候选物。
medRxiv. 2024 May 12:2024.05.11.24307175. doi: 10.1101/2024.05.11.24307175.
5
Development of an anti-Pfs230 monoclonal antibody as a Plasmodium falciparum gametocyte blocker.开发一种抗Pfs230单克隆抗体作为恶性疟原虫配子体阻断剂。
Res Sq. 2023 Dec 19:rs.3.rs-3757253. doi: 10.21203/rs.3.rs-3757253/v1.
6
Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine.评估一种新的融合抗原，即恶性疟原虫生殖细胞特异性 1 抗原的 cd 环和 HAP2-GCS1 结构域（cd-HAP），与各种佐剂联合配制，作为一种传播阻断疫苗。
Malar J. 2023 Dec 9;22(1):374. doi: 10.1186/s12936-023-04798-7.
7
Malaria & mRNA Vaccines: A Possible Salvation from One of the Most Relevant Infectious Diseases of the Global South.疟疾与 mRNA 疫苗：一种可能拯救全球南方最相关传染病之一的方法。
Acta Parasitol. 2023 Dec;68(4):916-928. doi: 10.1007/s11686-023-00712-y. Epub 2023 Oct 12.
8
The structure of a Plasmodium vivax Tryptophan Rich Antigen domain suggests a lipid binding function for a pan-Plasmodium multi-gene family.恶性疟原虫色氨酸丰富抗原结构域的结构提示一个泛疟原虫多基因家族具有脂质结合功能。
Nat Commun. 2023 Sep 14;14(1):5703. doi: 10.1038/s41467-023-40885-8.
9
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle.一种由单组分60拷贝Pfs230D1纳米颗粒设计而成的高效且持久的疟疾传播阻断疫苗。
NPJ Vaccines. 2023 Aug 18;8(1):124. doi: 10.1038/s41541-023-00709-8.
10
Plasmodium falciparum Gametes and Sporozoites Hijack Plasmin and Factor H To Evade Host Complement Killing.恶性疟原虫配子体和子孢子劫持纤溶酶原和因子 H 逃避宿主补体杀伤。
Microbiol Spectr. 2023 Jun 15;11(3):e0449322. doi: 10.1128/spectrum.04493-22. Epub 2023 May 16.
本文引用的文献
1
Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity.单克隆抗表皮生长因子受体抗体，其为表皮生长因子结合的抑制剂以及表皮生长因子刺激的酪氨酸蛋白激酶活性的拮抗剂。
J Biol Chem. 1984 Jun 25;259(12):7755-60.
2
Alpha-factor-directed synthesis and secretion of mature foreign proteins in Saccharomyces cerevisiae.酿酒酵母中α因子导向的成熟外源蛋白的合成与分泌。
Proc Natl Acad Sci U S A. 1984 Aug;81(15):4642-6. doi: 10.1073/pnas.81.15.4642.
3
Characterization of recombinant human epidermal growth factor produced in yeast.酵母中产生的重组人表皮生长因子的特性分析。
Biochemistry. 1988 Jan 26;27(2):797-802. doi: 10.1021/bi00402a046.
4
Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito.恶性疟原虫有性阶段抗原的顺序表达，这些抗原可被蚊子体内的传播阻断抗体识别。
J Exp Med. 1985 Nov 1;162(5):1460-76. doi: 10.1084/jem.162.5.1460.
5
Regulated transcriptional systems for the production of proteins in yeast: regulation by carbon source.
Biotechnology. 1989;13:83-108.
6
Expression and processing of biologically active fibroblast growth factors in the yeast Saccharomyces cerevisiae.
J Biol Chem. 1988 Nov 5;263(31):16471-8.
7
The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies.恶性疟原虫的230-kDa配子体表面蛋白也是传播阻断抗体的靶标。
J Immunol. 1987 Dec 15;139(12):4213-7.
8
Immunogenicity of recombinant Plasmodium falciparum SERA proteins in rodents.
Mol Biochem Parasitol. 1991 Mar;45(1):159-70. doi: 10.1016/0166-6851(91)90038-8.
9
Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus.
Science. 1991 May 31;252(5010):1310-3. doi: 10.1126/science.1925544.
10
Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein.用重组包膜蛋白免疫的人体中，针对人类免疫缺陷病毒糖蛋白gp120保守区域的CD4 + T细胞的致敏作用
Proc Natl Acad Sci U S A. 1990 Aug;87(16):6136-40. doi: 10.1073/pnas.87.16.6136.
Zotero 插件